AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02262234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 2
Description: The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
Study NCT03136367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Option Grid
Description: The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
Study NCT04546815 — intervention group
Intervention type: DRUG
Intervention: Daptomycin
Description: According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-induced hypoglycemia
Description: During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia
Description: During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise-induced hypoglycemia
Description: During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
Study NCT03136367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picture Option Grid
Description: The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
Study NCT03328585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I in person
Description: 6 weeks of CBT-I in person, one 1-hour long session per week
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV or IT
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT00390793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT04780035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Description: The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart.
Study NCT04780035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)
Description: The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
Study NCT03379740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: Subject's own e-cigarette
Study NCT03379740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-1.7%
Description: P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-induced hypoglycemia
Description: During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
Study NCT03379740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-1.7%LA
Description: P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
Study NCT04209556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 100 mg QD
Description: Investigational Product
Study NCT03328585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I via Telemedicine
Description: 6 weeks of CBT-I via telemedicine, one 1-hour long session per week
Study NCT03328585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
Study NCT02180217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Description: Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
Study NCT02180217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699 matching placebo
Description: Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
Study NCT03379740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-3%LA
Description: P4M3 e-liquid concentration of 3% nicotine with lactic acid
Study NCT03379740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P4M3-4%LA
Description: P4M3 e-liquid concentration of 4% nicotine with lactic acid
Study NCT04209556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 300 mg QD
Description: Investigational Product
Study NCT04209556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 600 mg QD
Description: Investigational Product
Study NCT04209556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo
Study NCT04209556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-6826647 400 mg QD
Description: Investigational Product
Study NCT00333619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonpharmacological sleep intervention
Description: The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
Study NCT00333619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
Study NCT02033109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-1005
Description: Intravaginal use
Study NCT02033109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC gel
Study NCT01606124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO
Study NCT02032225 — intervention group
Intervention type: OTHER
Intervention: Skin biopsy
Study NCT01606124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01606124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01606124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01606124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01606124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02370758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir or Ganciclovir
Study NCT03475524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 1000 Mg Oral Tablet
Description: oral tablet 1ooomg systemic metformin will be given to group
Study NCT03753048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Y-Graft
Description: Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
Study NCT03753048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-Situ
Description: In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
Study NCT02875470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensiv Perio Set
Description: Diamond burs for root planing
Study NCT02875470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey curette
Study NCT03475524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral placebos will be given to control beside trichloracetic acid peeling
Study NCT03475524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trichloroacetic Acid Peeling
Description: Trichloroacetic acid peeling to the three groups
Study NCT01348165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution
Study NCT02566252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: PUL-042
Study NCT02566252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Description: Pre-treatment
Study NCT03475524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic Acid Peeling
Description: Trichloroacetic acid peeling to the three groups
Study NCT03475524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: oral tablet 500 mg
Study NCT02566252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate
Description: Pre-treatment
Study NCT01828944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil
Study NCT00148356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZoMaxx™ Drug-Eluting Coronary Stent System
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT00148356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study NCT02649764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02649764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02649764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02649764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Given IV
Study NCT00313560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
Study NCT01595477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Group
Description: Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30mg intravenous infusion on days 0 (transplant), 1, and 2
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
Study NCT01828944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive oil
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 2mg orally twice daily, on days 1-60
Study NCT00078559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
Study NCT01828944 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Study NCT02296853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF
Description: 25 mg tablet administered orally
Study NCT02296853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally
Study NCT05484128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastrus
Description: Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475.~Gastrus will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus.
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (or equivalent)
Description: 250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)/Sulfa (Bactrim, Septra)
Description: 1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valgancyclovir
Description: Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: 400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: 300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Description: 10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
Study NCT00078559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: 500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
Study NCT05484128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo has an identical preparation to Gastrus
Study NCT03648762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise Intervention
Description: Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
Study NCT04265170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlastX with negative pressure therapy
Description: Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
Study NCT04639401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: motor entrainment to auditory cues and music during walking on quality of movement
Description: The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
Study NCT04639401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor entrainment to auditory cues and music during walking on quality of movement
Description: The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
Study NCT03648762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combined Aerobic and Strength Exercise Intervention
Description: Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
Study NCT03648762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inspiratory Muscle Training Exercise Intervention
Description: Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
Study NCT02168933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 308 nm excimer laser
Description: Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
Study NCT02168933 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser treatment to the control side biweekly for a total of 8 weeks.
Study NCT02101840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apo-Oxycodone CR®
Description: a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
Study NCT02101840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyNEO®
Description: a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
Study NCT02101840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
Study NCT00506948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: 15 mg/kg by vein or by mouth every 12 hours.